세계의 신경 퇴행성 질환 시장 : 장래 예측 - 분자 유형별, 적응증별, 약제 클래스별, 투여 경로별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Neurodegenerative Disease Market is accounted for $64.4 billion in 2025 and is expected to reach $118.9 billion by 2032 growing at a CAGR of 9.15% during the forecast period. Neurodegenerative disease refers to a group of disorders characterized by the progressive loss of structure or function of neurons, leading to their gradual death. These conditions affect the brain and nervous system, impairing cognitive, motor, and sensory functions. Common examples include Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The underlying causes often involve abnormal protein accumulation, genetic mutations, oxidative stress, and mitochondrial dysfunction. As neurons cannot regenerate efficiently, these diseases are typically chronic and worsen over time. Neurodegenerative diseases pose significant medical and social challenges due to their complexity and lack of curative treatments.

Market Dynamics:

Driver:

Advances in biomarker & diagnostic technology

Researchers are developing fluid-based and imaging biomarkers to identify early-stage pathology in Alzheimer's, Parkinson's, and ALS. Integration with AI and machine learning is improving diagnostic accuracy and disease stratification. Pharmaceutical companies are using biomarkers to optimize trial design and therapeutic targeting. Companion diagnostics are gaining traction across precision neurology pipelines. These capabilities are propelling innovation in early intervention and personalized care.

Restraint:

Complex disease biology & heterogeneity

Many conditions involve multifactorial pathogenesis, including genetic, environmental, and inflammatory components. Disease progression varies widely across individuals, complicating trial endpoints and treatment response. Lack of validated animal models and translational biomarkers slows preclinical research. Regulatory bodies require robust evidence for efficacy and safety in heterogeneous populations. These challenges continue to hinder drug development and platform scalability.

Opportunity:

Rising healthcare spending & awareness

Governments are funding national dementia strategies and aging-related research programs. Public campaigns are improving awareness and reducing stigma around cognitive decline and neurological disorders. Hospitals are expanding memory clinics and neurorehabilitation centers to meet rising demand. Investment in digital health and remote monitoring is supporting long-term care and disease management. These trends are fostering growth across prevention, diagnosis, and therapeutic innovation.

Threat:

Limited diagnostic access in low-resource settings

Many regions lack trained neurologists, imaging infrastructure, and molecular testing capabilities. Rural and underserved populations face delays in diagnosis and limited access to specialized care. Cost and availability of PET scans, CSF assays, and genetic testing remain barriers in emerging markets. Fragmented referral pathways and low public awareness further degrade care quality. These constraints continue to hamper equity and outcomes across global neurodegenerative ecosystems.

Covid-19 Impact:

The pandemic disrupted clinical trials, diagnostics, and long-term care for neurodegenerative patients worldwide. Lockdowns and resource reallocation delayed therapy access and disease monitoring. However, post-pandemic recovery strategies have emphasized resilience and digital transformation in neurology care. Telemedicine, remote cognitive assessments, and digital biomarkers gained traction across aging populations. Public awareness of neurological health increased during the crisis, influencing policy and research priorities. These shifts are accelerating investment in infrastructure, innovation, and patient-centric care models.

The alzheimer's disease segment is expected to be the largest during the forecast period

The alzheimer's disease segment is expected to account for the largest market share during the forecast period due to its high prevalence, diagnostic complexity, and therapeutic innovation. Pharmaceutical firms are launching monoclonal antibodies and disease-modifying therapies targeting amyloid and tau pathology. Investment in early detection and risk stratification is rising across aging populations. Integration with digital cognitive tools and fluid biomarkers is improving screening and monitoring. Governments are funding dementia research and care coordination programs.

The cell & gene therapies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cell & gene therapies segment is predicted to witness the highest growth rate as curative approaches gain traction across rare and progressive neurodegenerative conditions. Developers are using viral vectors, stem cells, and gene editing platforms to restore neuronal function and halt disease progression. Regulatory bodies are offering expedited review and conditional approvals for breakthrough therapies. Investment in manufacturing scale-up and delivery platforms is improving readiness and affordability. Partnerships between biotech firms, hospitals, and payers are supporting access and reimbursement models.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure, regulatory engagement, and aging demographics. The United States and Canada host major neurology centers, clinical trial networks, and patient advocacy organizations. FDA programs such as Fast Track and Breakthrough Therapy Designation are supporting innovation and market entry. Investment in biomarker development and precision neurology is driving platform expansion. Presence of leading biotech firms and academic institutions is reinforcing leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, aging populations, and policy reform converge. Countries like China, Japan, India, and South Korea are scaling neurology diagnostics and therapy access across urban and rural regions. Government-backed programs are supporting dementia screening, public awareness, and infrastructure development. Regional biotech firms are launching cell and gene therapies tailored to population-specific indications. Demand for affordable and scalable solutions is rising across public and private healthcare systems. These trends are accelerating regional growth across neurodegenerative disease ecosystems.

Key players in the market

Some of the key players in Neurodegenerative Disease Market include AbbVie Inc., Amneal Pharmaceuticals LLC, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., Biogen Inc., Eli Lilly and Company, Johnson & Johnson, Eisai Co., Ltd., Lundbeck A/S and Denali Therapeutics Inc.

Key Developments:

In January 2025, AbbVie exercised its first opt-in under the collaboration with Capsida Biotherapeutics, securing rights to a gene therapy program for neurodegenerative diseases. The decision followed promising primate data showing effective delivery of AbbVie's therapeutic payload to the brain using Capsida's engineered AAV capsids, while minimizing off-target effects in the liver and dorsal root ganglia.

In September 2023, Amneal launched IPX203 in the U.S. following FDA approval for Parkinson's disease. The extended-release formulation demonstrated superior "on-time" versus immediate-release carbidopa-levodopa in Phase 3 trials, offering improved symptom control and dosing convenience for patients with advanced Parkinson's.

Molecule Types Covered:

• Small-Molecule Drugs
• Biologics
• Cell & Gene Therapies

Indications Covered:

• Alzheimer's Disease
• Parkinson's Disease
• Huntington's Disease
• Amyotrophic Lateral Sclerosis (ALS)
• Multiple Sclerosis (MS)
• Spinal Muscular Atrophy (SMA)
• Other Indications

Drug Classes Covered:

• N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Dopamine Agonists & Inhibitors
• Cholinesterase Inhibitors
• Monoclonal Antibodies
• Gene & RNA-Based Therapies
• Other Drug Classes

Route of Administrations Covered:

• Oral
• Injectable
• Transdermal
• Intranasal

End Users Covered:

• Hospitals & Clinics
• Research & Academic Institutes
• Pharmaceutical & Biotech Companies
• Patient Advocacy Groups
• Other End-Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Neurodegenerative Disease Market, By Molecule Type

• 5.1 Introduction
• 5.2 Small-Molecule Drugs
• 5.3 Biologics
• 5.4 Cell & Gene Therapies

6 Global Neurodegenerative Disease Market, By Indication

• 6.1 Introduction
• 6.2 Alzheimer's Disease
• 6.3 Parkinson's Disease
• 6.4 Huntington's Disease
• 6.5 Amyotrophic Lateral Sclerosis (ALS)
• 6.6 Multiple Sclerosis (MS)
• 6.7 Spinal Muscular Atrophy (SMA)
• 6.8 Other Indications

7 Global Neurodegenerative Disease Market, By Drug Class

• 7.1 Introduction
• 7.2 N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
• 7.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
• 7.4 Dopamine Agonists & Inhibitors
• 7.5 Cholinesterase Inhibitors
• 7.6 Monoclonal Antibodies
• 7.7 Gene & RNA-Based Therapies
• 7.8 Other Drug Classes

8 Global Neurodegenerative Disease Market, By Route of Administration

• 8.1 Introduction
• 8.2 Oral
• 8.3 Injectable
• 8.4 Transdermal
• 8.5 Intranasal

9 Global Neurodegenerative Disease Market, By End User

• 9.1 Introduction
• 9.2 Hospitals & Clinics
• 9.3 Research & Academic Institutes
• 9.4 Pharmaceutical & Biotech Companies
• 9.5 Patient Advocacy Groups
• 9.6 Other End-Users

10 Global Neurodegenerative Disease Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 AbbVie Inc.
• 12.2 Amneal Pharmaceuticals LLC
• 12.3 Boehringer Ingelheim GmbH
• 12.4 F. Hoffmann-La Roche Ltd.
• 12.5 Merck & Co., Inc.
• 12.6 Novartis AG
• 12.7 Pfizer Inc.
• 12.8 Teva Pharmaceutical Industries Ltd.
• 12.9 UCB S.A.
• 12.10 Biogen Inc.
• 12.11 Eli Lilly and Company
• 12.12 Johnson & Johnson
• 12.13 Eisai Co., Ltd.
• 12.14 Lundbeck A/S
• 12.15 Denali Therapeutics Inc.